Rettsyndrome.org invests $1.5 million in new 2014 awards

August 18, 2014

(Cincinnati, OH) The International Rett Syndrome Foundation now doing business as Rettsyndrome.org announces today that the Board of Trustees has awarded $1.5M to support 10 new grants to further translational research and launch of the neuro-habilitation therapeutic program, and fund clinical research.

Five of the grants fund the Translational Research Program which funds early and late stage translational research to treat and reverse Rett syndrome (RTT).

An additional five grants were awarded to the newly established Neuro-Habilitation Program. The goal of the program is to identify the best cognitive therapies, physical therapies, occupational therapies and speech therapies that will aid in establishing the networks critical for skill development in Rett syndrome. Today's new awards and the upcoming annual summer call for basic discovery research, training fellowships, and translational research in pharmacologic treatments will contribute to Rettsyndrome.org's program for bringing "Research to a Reality". Rettsyndrome.org has advanced our comprehensive strategy to accelerate discoveries in fundamental research toward clinical to improve the lives and treatment of those living with Rett syndrome. Our emphasis on translational and clinical research will ensure that new ideas are constantly flowing into the drug pipeline and neuro-habilitation platforms both aimed at accelerating the treatments and maximizing function in Rett syndrome.

Rettsyndrome.org's Chief Science Office, Steve Kaminsky, PhD comments on the research strategy, "With potential treatments on the horizon, we have coined the phrase that our pharmacologic treatments are designed to "correct Rett biology". However, as we proceed down this road, we have to identify new technologies and therapies that "reset the neurology" in Rett syndrome to maximize our girls' abilities. To this end, we have initiated a new program this year and it is called our Neuro-Habilitation Program. The time is right to begin looking at this area of research so that the fruits of this labor mature at the same time as our other research programs which identify pharmacologic treatments. My hope is that the work will converge on each other, and we can match the best practices in drug therapy to the best practices in neuro-habilitation therapy."

The mission of Rettsyndrome.org is to advance research towards new treatments for Rett syndrome by investing in both basic and translational research grants, which are vetted through a rigorous process of peer-review by members of Rettsyndrome.org's Scientific Review Board (SRB). Those applications that have the highest scientific and programmatic merit are recommended to the Board of Trustees for final funding decisions. New 2014 Rettsyndrome.org Awards

ANGEL "NLX-101 - a novel, highly selective and potent serotonergic 5-HT1A receptor agonist for the treatment of respiratory arrhythmias in Rett Syndrome: a pre-clinical proof-of-principle study in murine models"

HeART Michela Fagiolini, PhD, Boston Children's Hospital "Assessing NMDAr modulators to ameliorate cortical regression in Rett Syndrome" HeART Awards - Neuro-Habilitation "Sensory Integration to Increase Functional Reaching in Children with Rett syndrome and related disorders" "Improving Upper Extremity Motor Skills in Children with RTT Using Selected Movements to Control Internet Virtual Reality Computer Games" HeART Awards - Scout Program Database Contracts "RettBASE" "InterRETT"
-end-
About the Rettsyndrome.org

Rettsyndrome.org is the leading private funder of Rett syndrome research and provider of family support programs to those touched by Rett syndrome. Through partnerships with local, national and international supporters, Rettsyndrome.org has invested more than $32 million in research leading to discoveries that allow us to test treatments for Rett syndrome in human clinical trials today. Rettsyndrome.org has earned Charity Navigator's most prestigious 4 star rating.

About Rett syndrome (RTT)

Rett syndrome is a rare genetic postnatal neurological disorder that occurs almost exclusively in girls and leads to severe impairments, affecting nearly every aspect of child's life: their ability to speak, walk, eat and breathe. The hallmark of Rett syndrome is near constant repetitive hand movements. Cognitive assessment in children with Rett syndrome is complicated, but we know that they understand far more than they can communicate to us, evidenced by their bright and attentive eyes, and their ability to express a wide spectrum of moods and emotions. To learn more about Rettsyndrome.org and Rett syndrome, visit http://www.rettsyndrome.org or call at 1-800-818-RETT (7388).

International Rett Syndrome Foundation

Related Rett Syndrome Articles from Brightsurf:

Proteins -- and labs -- coming together to prevent Rett syndrome
Two labs investigated whether the disruption of one protein's condensate-forming ability contributes to Rett syndrome.

Genetic editing milestone in mouse model of Rett Syndrome
A genomic error that causes Rett Syndrome, a serious lifelong neurological disorder, can be corrected in the brains of mice by rewriting the genetic instructions carried by the RNA.

Yale researchers find potential treatment for Rett Syndrome
An experimental cancer drug can extend the life of mice with Rett Syndrome, a devastating genetic disorder that afflicts about one of every 10,000 to 15,000 girls within 6 to 18 months after birth, Yale researchers report June 10 in the journal Molecular Cell.

Research team investigates abnormal neuron activity in Rett syndrome
Research by Billy Lau, a postdoctoral researcher working with Assistant Professor Keerthi Krishnan at the University of Tennessee, Knoxville, examines the time during which an adult female mouse first learns to recognize and respond to the distress cries of young mouse pups as an opportunity for the brain to rewire and learn again.

A dietary supplement improves skills of an atypical Rett syndrome patient
Administration of the amino acid L-serine, a dietary supplement, contributes to the improvement of the communicative and motor skills of a patient with a mutation that alters glutamate receptors.

A new drug shows preclinical efficacy in Rett syndrome
A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models.

X chromosome reactivation could treat Rett syndrome, other X-linked disorders
A study from a team of Massachusetts General Hospital investigators points toward a potential strategy for treating X-linked disorders -- those caused by mutations in the X chromosome -- in females.

Discovery fuels hope for Rett syndrome treatment
Vanderbilt University researchers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.

Drug improves brain performance in Rett syndrome mice
A brain penetrant drug -- a small-molecule mimetic of BDNF, or brain derived neurotrophic factor -- is able to improve brain performance in Rett syndrome mice -- specifically synaptic plasticity in the hippocampus and object location memory.

Small-molecule therapeutic boosts spatial memory and motor function in Rett syndrome mice
Rett syndrome is a neurological disorder affecting learning and development, caused by a mutation in the MECP2 gene triggering decreased levels of brain-derived neurotrophic factor (BDNF).

Read More: Rett Syndrome News and Rett Syndrome Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.